A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
AURORA Study: Iloprost for Subjects with Systemic Sclerosis (SSc-Raynaud's Phenomenon)
Sponsor: Eicos Sciences, Inc.
Enrolling: Male and Female Patients
Study Length: 35 Days
Clinic Visits: 7
IRB Number: AAAS5867
U.S. Govt. ID: NCT04040322
Contact: Biiftu Duresso: 212-342-6815 / bjd2134@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out whether a drug called iloprost is safe to use in people with systemic sclerosis (SSc) (Raynaud's phenomenon), and whether it may help decrease symptomatic digital ischemic episodes (episodes in the fingers).
This study is closed
Investigator
Elana Bernstein, MD
Do You Qualify?
Have you been diagnosed with systemic sclerosis (scleroderma)? Yes No
Do you experience Raynaud's phenomenon? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Biiftu Duresso
bjd2134@cumc.columbia.edu
212-342-6815
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE